Galmed Pharmaceuticals
GLMD
44 hedge funds and large institutions have $102M invested in Galmed Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.
591% more capital invested
Capital invested by funds: $14.8M → $102M (+$87.4M)
357% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 7
132% more funds holding
Funds holding: 19 → 44 (+25)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.13% more ownership
Funds ownership: 0.1% → 0.23% (+0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$14.2M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$6.38M |
| 3 |
6CM
683 Capital Management
New York
|
+$5.64M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$5.12M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$2.03M |
| 2 |
Renaissance Technologies
New York
|
-$500K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$398K |
| 4 |
JGC
J. Goldman & Co
New York
|
-$145K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$107K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EMG
51
ETF Managers Group
Summit,
New Jersey
| – | -$76K | -84 | Closed |
|
52
JP Morgan Chase
New York
| – | -$21K | -21 | Closed |
|
GLMD Hedge Fund Activity: Q2 2018 in Review
44 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2018, worth a combined $102M — up 591% from $14.8M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new GLMD positions and 7 closed out — a net gain of 25 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $14.2M. The largest seller was Park West Asset Management, exiting entirely with an estimated $2.03M sold.
- 44 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2018, up from 19 in Q1 2018.
- Funds reported $102M of Galmed Pharmaceuticals stock for Q2 2018, up 591% quarter-over-quarter.
- 32 funds opened new Galmed Pharmaceuticals positions in Q2 2018 and 7 closed out, a net change of +25 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2018 was BVF Inc, an estimated $14.2M added.
- The largest Galmed Pharmaceuticals seller in Q2 2018 was Park West Asset Management, an estimated $2.03M sold.
Based on aggregated 13F filings for Q2 2018.